Kyle Dunton

Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study

Giuseppe Curigliano, Kyle Dunton, Mats Rosenlund et al. · Annals of Oncology · 2023 · 41 citations · Full text

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial

Tanja Fehm, Francesco Cottone, Kyle Dunton et al. · The Lancet Oncology · 2024 · 35 citations · Full text

Prevalence and Patient Outcomes of Adult Primary Hypercholesterolemia and Dyslipidemia in the UK: Longitudinal Retrospective Study Using a Primary Care Dataset from 2009 to 2019

Aikaterini Bilitou, John Were, Archie Farrer et al. · SHILAP Revista de lepidopterología · 2022 · 29 citations · Full text

217O Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)

Naoto T. Ueno, William Jacot, Toshinari Yamashita et al. · Annals of Oncology · 2022 · 18 citations · Full text

Patient-reported Outcomes, Breast Oncology, Medicine +7